Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medlive Technology CoHKSE:02192 +0.90%90 ROA % is 7.01% as of Dec. 2025, which is 9% above its 10-year median of 6.43. GuruFocus rates HKSE:02192 with a GF Score™ of 90/100 and a GF Value™ of HK$14.95 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 679 Healthcare Providers & Services companies, Medlive Technology Co ranks better than 73.34% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Medlive Technology Co's annualizedNet Income for the quarter that ended in Dec. 2025 was HK$395.5 Mil.
Medlive Technology Co's average Total Assets over the quarter that ended in Dec. 2025 was HK$5,640.9 Mil. Therefore, Medlive Technology Co's annualized ROA % for the quarter that ended in Dec. 2025 was 7.01%.
The historical rank and industry rank for Medlive Technology Co's ROA % or its related term are showing as below:
HKSE:02192'
s ROA % Range Over the Past 10 Years
Min: 1.87 Med: 6.43 Max: 51.03
Current: 6.59
During the past 8 years, Medlive Technology Co's highest ROA % was 51.03%. The lowest was 1.87%. And the median was 6.43%.
HKSE:02192's ROA % is ranked better than 73.34% of 679
companies
in the Healthcare Providers & Services industry
Industry Median: 1.93
vs HKSE:02192: 6.59
Medlive Technology Co (HKSE:02192) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Medlive Technology Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medlive Technology Co ROA % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medlive Technology Co's ROA % distribution charts can be found below:
* The bar in red indicates where Medlive Technology Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Medlive Technology Co (HKSE:02192) has a ROA % of 7.01% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Medlive Technology Co and its competitors. This is near median its historical median of 6.43. Over the past decade, Medlive Technology Co's ROA % has ranged from 1.87 to 51.03. According to the industry distribution chart, Medlive Technology Co ranks #181 out of 679 companies in the Healthcare Providers & Services industry, placing it in the top 26.7%.
Is Medlive Technology Co's ROA % too high?
Medlive Technology Co's current ROA % of 7.01% is near median its 10-year median of 6.43. Over the past 10 years, this metric has ranged from a low of 1.87 to a high of 51.03. The Healthcare Providers & Services industry median ROA % is 1.93. Medlive Technology Co's value of 7.01% is 263.2% above this industry median. Based on the distribution chart, Medlive Technology Co ranks #181 out of 679 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Medlive Technology Co has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medlive Technology Co's ROA % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Medlive Technology Co ranks #181 out of 679 companies for ROA %. This puts Medlive Technology Co in the upper half of its industry. The industry median ROA % is 1.93. Medlive Technology Co's value of 7.01% is 263.2% above this benchmark. Historically, Medlive Technology Co's own ROA % has ranged from 1.87 to 51.03 over the past decade. While the company's 10-year median is 6.43 vs. the industry median of 1.93, Medlive Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Healthcare Providers & Services company?
The median ROA % among Healthcare Providers & Services companies is 1.93, based on 679 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medlive Technology Co's current ROA % of 7.01% is 263.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Medlive Technology Co and its competitors. For the Healthcare Providers & Services industry, the median ROA % is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medlive Technology Co's current ROA % is 7.01%, which is near median its own 10-year median of 6.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medlive Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Medlive Technology Co (HKSE:02192) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$14.95, compared to a current price of HK$7.87 — trading 47.4% below its estimated fair value. The current ROA % is 7.01%, which is near median its 10-year median of 6.43 and 263.2% above the Healthcare Providers & Services industry median of 1.93. Medlive Technology Co's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Medlive Technology Co (HKSE:02192), the current ROA % is 7.01% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medlive Technology Co (HKSE:02192) Overvalued in 2026?
Based on GuruFocus' analysis, Medlive Technology Co stock appears to be undervalued.
The current stock price of HK$7.87 is trading 47.4% below its estimated GF Value™ of HK$14.95.
GuruFocus considers Medlive Technology Co to be Significantly Undervalued.
Key valuation signals for HKSE:02192:
ROA %: 7.01% (near median its 10-year median of 6.43)
GF Value™: HK$14.95 vs. price of HK$7.87 (47.4% below fair value)
Industry Position: 263.2% above the Healthcare Providers & Services median (#181 of 679)
No single metric tells the full story. See the HKSE:02192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medlive Technology Co Ltd is a digital healthcare marketing company that produces customized content for pharmaceutical and medical device firms. The company developed into a professional provider of medical information services and precision digital marketing services. Its platform also provides medical content consisting of third-party research, informal discussions, and medical news articles. The company also operates a minor internet hospital and a SaaS solution that helps with medical conferences and clinical research.
90GF Score
Get the complete analysis for HKSE:02192
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02192 has been successfully added to your 
